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found to have adequate knowledge and practice. Significant associations were 
noted for knowledge-practice groups with parent’s age, education level, and family 
income (p< 0.05). ConClusions: Understanding parents’ knowledge and practice 
is an important factor in order to improve immunization uptake and timeliness. 
Educational interventions targeting parents with inadequate knowledge and prac-
tice about childhood immunization are needed.
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objeCtives: Women of childbearing age are more likely to suffer from depression 
and anxiety disorders. Maternal depression has been associated with adverse birth 
outcomes such as preterm delivery, low birth weight/small for gestational age, etc. 
The objectives of this study are (i) to determine the prevalence of antidepressant 
utilization in pregnant women (ii) to identify factors associated with the use of 
antidepressants during pregnancy. Methods: We used data of 1428 United States 
women (age ≥ 20 years) who participated in the National Health and Nutrition 
Examination Survey (NHANES) from 2001 to 2012 (this is a cross-sectional health 
examination survey of the US population) and who were known to be pregnant at 
the time of the interview. Antidepressant utilization was assessed as reported by the 
study participants. Logistic regression models were used to identify factors associ-
ated with receiving an antidepressant during pregnancy. Results: The prevalence 
of antidepressant use increased from 3.1 % to 9.7% in from 2001 to 2012 (p< 0.01). 
Among those women who reported using antidepressants 15.45% had a diagnosis of 
clinical depression. Selective Serotonin Reuptake Inhibitors (SSRIs) were found to be 
the most commonly prescribed class of antidepressants (78.9%). Race was found to 
be a strong predictor of antidepressant use, Non-Hispanic White women were found 
to be more likely to be on antidepressants as compared to other races (OR = 3.1; 
95%CI 1.95 – 4.56). The other factors found to be significantly associated with anti-
depressant use were age, diagnosis of depression, and education. ConClusions: 
Utilization of antidepressants during pregnancy has increased in the past decade, 
specially the use of SSRIs. The prescription of antidepressants varies significantly 
by age, race, and education. Although an increase in antidepressant use potentially 
signifies treatment of maternal depression, it stresses the need for clinical guide-
lines to treat maternal depression.
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objeCtives: Birthweight is a strong predictor of an individual baby’s survival as 
well as overall infant mortality and low birthweight is associated with adverse 
health outcomes. This study utilized a linear regression model to predict a child’s 
birthweight from the mother’s race, education level, smoking status, and gestation 
age. Methods: A publically available dataset of births in Philadelphia, PA from 
1990 had 1,115 observations on five variables: mother’s race, years of education, 
and smoking status during pregnancy; and gestational age (weeks) and birthweight 
(gms). The dataset was randomly divided into 2 subsets for model development and 
validation. The model was developed against the development dataset, verified 
against the validation dataset, and refitted to the entire sample to generate the final 
results. Results: The final fitted model was: Y = b0 + b1X1 + b2X3 + b3X4 + b4X1X3 
+ b5 X42 (R2= 0.5337, Ra2= 0.5316, p< .0001); where X1 indicates the mother’s race was 
black, X3 indicates the mother smoked during pregnancy, and X4 represents gesta-
tion age (centered). Mother’s education was dropped from the model due to lack of 
significance. Negative effects were observed for race (b1= -227.22, 95% CI: [-287.01, 
-167.43], p< .0001) and smoking (b2= -316.59, 95% CI: [-414.16, -219.02], p< .0001), while 
a positive effect was observed for the interaction of race and smoking (b4= 210.31, 
95% CI: [86.80, 333.82], p= .0009). With respect to gestation age, the positive linear 
effect (b3= 144.90, 95% CI: [129.63, 160.16], p< .0001) was slightly offset by a small 
negative quadratic effect (b5= -1.47, 95% CI: [-2.84, -0.10], p= .0351). ConClusions: 
The results indicate that premature birth, mother’s race, and smoking during preg-
nancy are risk factors for lower birthweight, but the combined effect of a black 
mother who smoked during pregnancy is sub-additive. Mother’s education is not 
an independent risk factor, after controlling for these other factors.
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objeCtives: There is an increasing trend of stillbirth in Mongolia for the last few 
years and Ulaanbaatar city is the 2nd most polluted city in the world by WHO. 
This study sought to determine the association of outdoor air pollution and risk 
of stillbirth. Methods: This was a case-control study. The case group consisted of 
909 stillbirths and the controls included 159 764 live births from singletons born 
in 2008-2013 in Ulaanbaatar. Air quality data between January 2007 and December 
2013 was obtained. Association between air pollution and stillbirth was determined 
using Logit regression. Odds ratios were estimated per 10-ppb change for nitrogen 
dioxide (NO2), sulfur dioxide (SO2) and for particulate matter with aerodynamic 
diameter ≤ 10 μ m (PM10), and 100-ppb change for carbon monoxide (CO) during 
different gestational periods. Results: Average duration of gestation for stillbirths 
were 24.7 weeks whereas for live births average duration was 38.5 weeks (p< 0.0001). 
28.2% of stillbirths occurred in spring. Stillbirth risk increased in association with 
10-ppb change for SO2 in all trimesters (OR= 1.01; CI 95% 0.99-1.03). Stillbirth risk also 
increased in association with 10-ppb change for NO2 in first-trimester (OR= 1.01; CI 
95% 0.96-1.07). 100-ppb change for CO during all trimesters of gestation increased 
risks of stillbirth (OR= 1.01; CI 95% 0.98-1.04). There was an increased risk of still-
births in association with 10-ppb change for PM10in first-trimester (OR= 1.02; CI 
95% 0.99-1.04). ConClusions: Exposure to outdoor air substances may increase 
the risk of stillbirth, and that the most susceptible time periods for exposure are 
during the first trimester of gestation.
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objeCtives: Infection rates associated with intrathecal baclofen pump (ITBP) pro-
cedures are 4.5-9%. Practice guidelines recommend appropriate administration of 
perioperative antimicrobial prophylaxis (cefazolin or vancomycin monotherapy) 
to reduce surgical infection, which is expected to decrease morbidity and mor-
tality, and control duration/cost of care. This study explored the prevalence and 
specific antibiotic prophylaxis (AP) used in pediatric patients undergoing ITBP 
placement and factors associated with compliance of AP use. Methods: Using 
Pediatrics Health Information System (PHIS), the study cohort comprised patients 
who had ITBP surgery (ICD-9 CM procedure code 86.06) within 3 days of admission, 
between 7/1/2004-12/31/2013, with minimum follow up 90 days. Exclusion criteria 
were prior infection, antibiotic use within 30 days of admission, and/or missing 
financial data. Chi-squared test and multivariate logistic regression were used to 
determine factors associated with compliance to AP administration in ITBP surger-
ies. Analyses used SAS®9.3 software. Results: 1561 patients met inclusion criteria. 
89.3% received AP; among those, 34.1% received at least dual coverage. The most 
frequently used antibiotics in surgery were cefazolin (N= 882, 62.3%), vancomycin 
(345, 24.4%) as per guideline recommendations. Documented AP administration 
compliance rates were 74.3%, 64.8%, 70.7%, and 58.4% in West, South, Midwest, and 
Northeast regions, respectively. Compared to surgeries in the Northeast, procedures 
in the West (Odds Ratio, 2.1, 95% confidence interval 1.4-3.0, p< 0.001) and Midwest 
(1.7, 1.2-2.4, p= 0.003) were more likely to have AP compliance. Black (0.71, 0.52-0.96, 
p= 0.025) and Hispanic (0.62, 0.45-0.86, p= 0.005) patients were less likely to have AP 
compliance in surgeries than White patients. There were no significant differences 
of compliance by age, sex, insurance, and diagnosis. ConClusions: Close to 70% 
of ITBP surgeries show compliance with perioperative AP guidelines. Geographic, 
race, and practice variation in ITBP antibiotic prophylaxis were found in this study. 
Future research is warranted to examine these variations and resultant impact on 
surgical infection and outcomes.
IndIvIdUal’s HealtH – cost studies
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objeCtives: To examine the fracture-related cost burden and healthcare 
resource utilization among post-menopausal women in the U.S. Medicare popu-
lation. Methods: Post-menopausal women were identified using International 
Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) diagnosis 
codes from the U.S. Medicare claims dataset from 01JAN2008 through 31DEC2012. 
The first fracture diagnosis date was designated as the index date. One year of 
continuous health plan enrollment was required for all patients pre- and post-
index date. A comparison group was created, identifying patients without fractures 
of the same age, region, gender and index year and were matched to case patients 
based on baseline Charlson Comorbidity Index scores. A randomly chosen index 
date for the comparison group reduced selection bias. Healthcare costs and utiliza-
tions were compared using 1:1 propensity score matching (PSM). Results: Before 
matching (n= 182,124), patients with fractures were more likely to be white (92.6% 
vs. 85.8%), reside in the Northeast U.S. region (19.4% vs. 16.4%), and have diagno-
sis of depression (18.0% vs. 13.0%) and chronic obstructive pulmonary disease 
(26.3% vs. 23.3%). After 1:1 PSM, 65,549 patients were included in each cohort and 
baseline characteristics were well-balanced. Significantly more post-menopausal 
women with fractures had inpatient admission (42.3% vs. 8.6%, p< 0.0001), outpa-
tient (80.3% vs. 48.7%, p< 0.0001), home health agency (31.2% vs. 6.9%, p< 0.0001) 
skilled nursing facility (SNF) (25.7% vs. 2.72%, p< 0.0001) and hospice admission 
(1.4% vs. 1.0%, p< 0.0001) claims. Higher healthcare resource utilization trans-
lated to higher costs for post-menopausal fracture patients, including inpatient 
($7,869 vs. $1,203, p< 0.0001), outpatient ($1,928 vs. $622, p< 0.0001), SNF ($5,980 
vs. $437, p< 0.0001), hospice ($338 vs. $244, p< 0.0001), pharmacy ($1,052 vs. $829, 
p< 0.0001) and total costs ($23,097 vs. $5,247, p< 0.0001), than for those in the com-
parison cohort. ConClusions: Post-menopausal women with fractures in the 
U.S. Medicare population had higher healthcare resource utilization and expen-
ditures than those without fractures.
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objeCtives: To understand the cost range for pediatric vaccine administration 
across different countries and to describe the costing methodologies employed 
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for its calculation. Methods: A PubMed search was performed using the key-
words: child/pediatrics, immunization, administration and direct service costs/
costs and cost analysis/economics/health care costs/cost/fees, medical/cost 
benefit analysis, limited to publications in English, for infants up to 23 months, 
from 2004 onwards. Publications not referring to pediatric vaccination, not stating 
vaccine administration cost alone, and review studies were excluded. Results: 
Fourteen out of 167 articles were included in the analysis. Eight (57%) studies 
were conducted in the US, two in the UK, and four in low/middle income coun-
tries. Vaccine administration settings were public/private combined (42%), public 
only (29%) and private only (29%). Six studies (43%) looked into any vaccination 
type, followed by Rotavirus (14%), and influenza vaccines (14%); all other vaccines 
29%. Ten studies (72%) used secondary data sources. Two studies employed pro-
spective primary data collection [Time and Motion (T&M) methodology, survey/
diary] and two studies used primary and secondary data combined. Four studies 
(29%) employed a top-down costing approach, two studies a bottom-up approach, 
and three studies a mixed method (no information for 5 studies). For half of the 
studies the cost calculation methodology was not clear. Administration cost per 
dose ranged from $0.4-$4.5 for low/middle income countries and from $5.2-$61 
for high income countries. Nine (64%) studies used vaccine administration cost 
as input into a pharmacoeconomic model, and six (36%) generated stand-alone 
results. ConClusions: Pediatric vaccine administration cost varies widely. 
Comparison of study results is difficult due to different country management 
practices, different costing structures, and different costing years. The cost was 
mainly calculated using secondary data. Only a few studies collected primary data. 
To generate more precise cost estimates, real-world evidence studies employing 
appropriate costing methodologies are warranted.
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objeCtives: Determine the cost to the Mexican health system, associated with the 
treatment of cervical cancer from 2004 to 2011 and to determine the cost associated 
with diagnosis and treatment of anogenital warts in the same period. Methods: 
Data from the databases of the general direction of health information and the 
epidemiological surveillance system (SUIVE) were analyzed to determine the inci-
dence reported by the government of cervical dysplasia, cervical cancer in situ 
and anogenital warts. Treatment costs were obtained according to DRG for cervical 
dysplasia and cervical cancer. For anogenital warts the cost was estimated accord-
ing to data obtained through a Delphi panel made in 2013 (accepted for publica-
tion in the Mexican Urology Journal Ref. UROMX-D-15-00004). Results: In the 
analyzed period of eight years, it was observed that there has been a decrease in 
spending in the treatment of cervical lesions by severe dysplasia or cancer in situ 
from 6,649,760,194 to 4,423,742,35 USD. Also the treatment of mild and moderate 
dysplasia has shown a decrease in spending from 22,798,807,215 to 21,507,746,764 
USD. In the other way, an increase in spending is observed when treating ano-
genital warts, this goes from 410,728,813 to 573,330,965 USD. ConClusions: The 
observed results are interesting to mention, since the decrease in the expense of 
treating cervical dysplasia may reflect greater Epidemiological surveillance and 
early diagnosis. But, is interestingly the increase in spending anogenital warts 
treatment, which can also be a result of increased diagnosis and awareness by 
health professionals. In México vaccination campaign against human papilloma 
virus began in 2007, we can’t currently assume a relationship between the cost 
of treating injuries and human papillomavirus vaccination, but is of great inter-
est to continue the observation of the impact that could have this public health 
intervention in the Mexican population, as well as the budgetary impact for 
México.
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objeCtives: Uterine fibroids (UF) are the most common benign gynecological 
tumors. Prevalence data range from 5% to 21% of adult women in reproductive age. 
Despite the progress in the development of modern effective drugs the primary 
treatment is still surgical interventions. At the same time, the trend in recent 
years of the increasing of the incidence of UF in younger women, expansion of 
childbearing age limits period necessitates the revision of management of UF. 
The aim of the study was to calculate the average cost of hormonal therapy of 
UF in Ukraine for a minimum period of 3 months, considering that the main 
aim of this therapy is to manage bleeding and pain symptoms and to provide 
pre-operative treatment of UF. Methods: We analyzed the cost of treatment 
hormones per patient for course. We used the real data from medical records 
of patients who were treated in the Lviv Regional Perinatal Center and Lviv 
Regional Clinical Hospital in 2014. We have analyzed almost 300 stories diseases 
for 2014. We used the prices from Ukrainian database of Morion company (Kiev) 
on 01.01.2015 (1 USD = 15,75 UAH). Results: In Ukraine for the treatment of UF 
often are used these treatment hormonal schemes. We calculated the costs for 
course per patient in 3 months duration. The treatment costs are: mifepristone 
(tab.50 mg №30) – $184 (◽2895); goserelin acetate (implant 3,6 mg) – $419 (◽6600)/
triptorelin (powder for susp. for injection 3,75 mg) – $571 (◽9000); ulipristal acetate 
(tab. 5 mg №28) – $595 (◽9375). ConClusions: Hormonal schemes of treatment 
are quite expensive for Ukrainian woman. In particular, the scheme of ulipristal 
is three times more expensive than the scheme with mifepristone. Almost all 
patients fully pay costs out-of-pocket. So implementation of health insurance 
and reimbursement policies of hormonal medicines is actual and on time in 
Ukraine.
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objeCtives: The aim of the study was to investigate the cost-effectiveness of 
13-valent pneumococcal conjugate vaccine (PCV-13) programme for children in 
Kazakhstan from the perspective of Ministry of Health. Methods: A Markov 
model was constructed to estimate the effects and directs costs of PCV-13 pro-
gramme compared to other PCV programmes for newborns initiated in Kazakhstan. 
Treatment efficacy and transition probabilities were synthesized from local regis-
tries of vaccination with 5 year follow-up. The characteristics of patient cohort and 
treatment costs (vaccine cost, monitoring, adverse effects management) in year 2014 
Kazakhstani tenge (KZT) were estimated from republican official sources. Annual 
3% discounting rate and 1 year cycles (with half-cycle corrections) were utilized 
for the model. Robustness of the model parameters was explored by one-way and 
probabilistic sensitivity analysis. Results: Analysis of the registries showed sig-
nificant decrease of incidence of diseases assosiated with S. pneumoniae in children 
that received the PCV-13. Moreover, the introduction of PCV-13 decreased the under 
1-age mortality due to pneumonia by half (95%CI, p value= 0.001). As a result of 5 
year stimulation of the model, the CER of PCV-13 was estimated as 8432 tenge/LYG 
or 8574 tenge/QALY, whereas CER for no PCV-13 was estimated as 7441 tenge/LYG 
or 7605 tenge/QALY. ICER was estimated as 122 070 tenge/QALY, which is within 
the cost-effectiveness threshold values recommended by WHO. ConClusions: 
The introduction of PCV-13 seems to be a cost-effective programme in Kazakhstan. 
These findings may better inform decision makers regarding formulary inclusion 
and reimbursement in the vaccine programmes in Kazakhstan.
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objeCtives: Mandatory employer-based insurance coverage of contraception in 
the U.S. has been a controversial component of the Affordable Care Act (ACA). Prior 
research has examined the cost-effectiveness of contraception in general; however, 
no studies have developed a formal decision-model in the context of the new ACA 
provisions. As such, this study aims to estimate the relative cost-effectiveness of 
contraception from the employer and societal perspectives, taking into considera-
tion newer regulations allowing for religious exemptions. Methods: A decision-
tree was developed from the employer and societal perspectives to simulate costs 
and outcomes associated with all contraceptive methods covered by the ACA. 
Method-specific estimates of contraception access, utilization, adherence, failure 
rates, outcomes, and costs were derived from the literature. Employer coverage rates 
and covariates (age, income, marital status, and access) were varied through sensi-
tivity analysis. Results: Compared to full coverage of contraception, providing no 
coverage resulted in 4.9 more pregnancies per 100 women of childbearing age. This 
subsequently increased the number of live births (3.6 per 100) and terminations (1.3 
per 100). Providing no coverage for contraception also resulted in greater societal 
healthcare costs owing to this increase in pregnancies. Coverage via a health sav-
ings account (HSA) resulted in a lower number of pregnancies and reduced costs 
due to the greater access to prescribing pharmacies. ConClusions: Although lack 
of coverage reduced drug costs, it ultimately resulted in a greater number of unin-
tended pregnancies. Whether the objection for coverage is due to costs or increasing 
terminations, denying full coverage of contraceptives appears to have the opposite 
consequence of increasing total costs as well as the total number of terminations. 
Coverage of contraceptives via an HSA may provide a compromise.
